Skip to main content
Year archive

PERCHERON THERAPEUTICS LIMITED — 2023 filings

All 56 regulatory filings released by PERCHERON THERAPEUTICS LIMITED (PER) in 2023, sourced directly from the official regulator.

56 Filings
2023 Period
2023 filings (56)
Filing Released Lang
Notification of cessation of securities - ANP 4 pages 24.3KB
Share Issue/Capital Change
2023-12-21 English
Notification regarding unquoted securities - ANP 8 pages 36.5KB
Capital/Financing Update
2023-11-29 English
Change of Director's Interest Notice (CG,JG) 4 pages 351.3KB
Director's Dealing
2023-11-29 English
Antisense completes Unmarketable Parcels facility 1
Share Issue/Capital Change
2023-11-26 English
Proposed issue of securities - ANP 7 pages 35.3KB
Capital/Financing Update
2023-11-23 English
Change of Director's Interest Notice (JG) 2 pages 282.9KB
Director's Dealing
2023-11-20 English
Annual General Meeting Presentation 20 pages 1.7MB
AGM Information
2023-11-14 English
Results of Annual General Meeting 2 pages 257.5KB
Declaration of Voting Results & Voting Rights Announcements
2023-11-14 English
Quarterly Activities/Appendix 4C Cash Flow Report 11 pages 1.5MB
Interim / Quarterly Report
2023-10-30 English
Notice of Annual General Meeting/Proxy Form 29 pages 953.9KB
AGM Information
2023-10-16 English
Change in substantial holding 4 pages 237.8KB
Regulatory Filings
2023-10-16 English
Antisense to participate in upcoming investor conferences 2 pages 101.1KB
Regulatory Filings
2023-10-15 English
Antisense launches Unmarketable Parcels facility 10 pages 604.1KB
Capital/Financing Update
2023-10-08 English
Change of Director's Interest Notice GP 2 pages 275.4KB
Director's Dealing
2023-10-01 English
Publication of final Long COVID data for ATL1102 2 pages 159.5KB
Regulatory Filings
2023-09-27 English
Positive Data for ATL1102 in Limb Girdle Muscular Dystrophy 2 pages 139.7KB
Regulatory Filings
2023-09-25 English
Antisense Therapeutics Corporate Presentation 19 pages 1.7MB
Investor Presentation
2023-08-27 English
Appendix 4E and Annual Report 61 pages 3.2MB
Annual Report
2023-08-24 English
Corporate Governance Statement 8 pages 185.7KB
Governance Information
2023-08-24 English
Appendix 4G 12 pages 260.9KB
Governance Information
2023-08-24 English
Application for quotation of securities - ANP 6 pages 27.6KB
Capital/Financing Update
2023-08-21 English
Change of Director's Interest Notice (CG,JG) 4 pages 303.7KB
Director's Dealing
2023-08-21 English
Antisense Share Purchase Plan (SPP) Raises $3.26 Million 1
Capital/Financing Update
2023-08-20 English
Commencement of Chief Executive Officer 1 page 93.9
Board/Management Information
2023-08-06 English
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 856.9KB
Interim / Quarterly Report
2023-07-27 English
Share Purchase Plan (SPP) Offer Booklet 18 pages 510.2KB
Capital/Financing Update
2023-07-27 English
Positive new DMD Combination Therapy Data in mdx mice 3 pages 148.5KB
Regulatory Filings
2023-07-25 English
Becoming a substantial holder 3 pages 154.7KB
Regulatory Filings
2023-07-24 English
Application for quotation of securities - ANP 6 pages 27.6KB
Share Issue/Capital Change
2023-07-23 English
Notice under Section 708A 1 page 172.2KB
Regulatory Filings
2023-07-23 English
Quarterly Activities Report 2 pages 250.9KB
Capital/Financing Update
2023-07-19 English
Intention to launch Share Purchase Plan 2 pages 250.9KB
Capital/Financing Update
2023-07-19 English
Proposed issue of securities - ANP 7 pages 31.1KB
Capital/Financing Update
2023-07-19 English
Institutional Placement and proposed Share Purchase Plan SPP 2 pages 137.8KB
Capital/Financing Update
2023-07-17 English
Proposed issue of securities - ANP 5 pages 28.1KB
Capital/Financing Update
2023-07-17 English
Trading Halt 2 pages 567.5KB
Capital/Financing Update
2023-07-13 English
MHRA approval for ATL1102 Phase IIb DMD clinical trial in UK 1
Regulatory Filings
2023-06-26 English
First Patient Dosed in ATL1102 Phase IIb DMD Trial 2 pages 104.1KB
Regulatory Filings
2023-06-07 English
Shareholder Newsletter 4 pages 156.2KB
Management Reports
2023-06-05 English
Final Director's Interest Notice 2 pages 279.4KB
Director's Dealing
2023-05-11 English
Change of Director's Interest Notice (JG) 2 pages 329.6KB
Director's Dealing
2023-05-10 English
Initial Director's Interest Notice 2 pages 238.4KB
Director's Dealing
2023-05-08 English
Chief Executive Officer and Managing Director Appointment 3 pages 184.1KB
Board/Management Information
2023-05-07 English
PIIb DMD trial approved in Bulgaria- UK, Australia advancing 2 pages 110.6KB
Regulatory Filings
2023-04-25 English
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 666.2KB
Interim / Quarterly Report
2023-04-16 English
Dosing commenced in the ATL1102 toxicology study 2 pages 142.4KB
Capital/Financing Update
2023-03-13 English
Application for quotation of securities - ANP 6 pages 28.0KB
Share Issue/Capital Change
2023-03-06 English
Notice under Section 708A 1 page 135.6KB
Share Issue/Capital Change
2023-03-06 English
Proposed issue of securities - ANP 5 pages 27.3KB
Capital/Financing Update
2023-03-05 English
Receipt of R&D Tax Incentive Payment 1 page 77.9KB
Regulatory Filings
2023-02-22 English
Half Yearly Report and Accounts 28 pages 1.2MB
Interim / Quarterly Report
2023-02-21 English
Presentation at International Conference on DMD 2 pages 104.1KB
Regulatory Filings
2023-02-16 English
First approval for ATL1102 Phase IIb DMD clinical trial 2 pages 103.4KB
Regulatory Filings
2023-02-13 English
Limb Girdle Muscular Dystrophy R2 animal study commenced 2 pages 111.4KB
Regulatory Filings
2023-02-12 English
Positive outcomes in DMD combination therapy animal study 5 pages 329.8KB
Regulatory Filings
2023-01-31 English
Quarterly Activities/Appendix 4C Cash Flow Report 8 pages 302.6KB
Interim / Quarterly Report
2023-01-24 English